IBA Advances Cancer Treatment with New Proton Therapy Contract
In a significant move for the future of cancer treatment, IBA (Ion Beam Applications S.A.), a leader in particle accelerator technology, has secured a deal to install a Proteus®ONE proton therapy system at a major hospital in Taiwan. This contract marks an important step forward in enhancing healthcare capabilities in the region.
Details of the Contract
The recent agreement includes the provision of the Proteus®ONE system, which is renowned for its compact design and cutting-edge technology in proton therapy. Alongside the system, IBA will also deliver a comprehensive Quality Assurance package through IBA Dosimetry. The innovative system is designed with flexibility in mind, allowing upgrades to ensure healthcare providers have access to the latest advancements.
DynamicARC Beam Delivery
One of the exciting features of the new installation will be the DynamicARC® beam delivery capabilities. Once regulatory approvals are secured, this advanced feature will enhance treatment accuracy and efficacy, offering patients in Taiwan an opportunity for improved cancer care.
Statements from Company Leaders
Olivier Legrain, the CEO of IBA, expressed his enthusiasm about this partnership, stating, "Securing this order is a significant achievement for us. There is a growing demand for our Proteus®ONE solution across Asia, and we are eager to collaborate with the team at the Tri-Service General Hospital, helping cancer patients benefit from our state-of-the-art technology.”
Impact on Patient Care
Dr. Chun-Shu Lin, a key figure at the Tri-Service General Hospital, shared his excitement about the introduction of proton therapy. He remarked, "The acquisition signifies a transformative leap in our commitment to providing advanced and compassionate care. Our patients will be among the first in Taiwan to receive treatment using this advanced technology, which is promising for their recovery journeys.”
Future of Proton Therapy in Taiwan
This contract marks the third order of the Proteus®ONE system in Taiwan, illustrating a robust interest in this advanced treatment method across the region. The hospital plans to initiate patient treatments by late 2028, aiming to integrate this innovative therapy into its offerings shortly.
The financial aspect associated with the implementation of the Proteus®ONE system is significant. Typically, the price, along with a multi-year maintenance contract, can range between EUR 35 and 45 million, reflecting the high value and cutting-edge nature of this healthcare investment.
About IBA and Its Commitment
Founded in Louvain-La-Neuve, Belgium, IBA has cemented its position as a leader in the field of particle accelerator technology. The company specializes in proton therapy, which is recognized as a cutting-edge method for treating cancer. With around 2,100 employees, IBA not only sets industry standards in technology but also emphasizes a commitment to social and environmental performance through its certification as a B Corporation.
Insights About Tri-Service General Hospital
The Tri-Service General Hospital, which has been in operation since 1946, is recognized as a premier medical center with a focus on providing high-quality healthcare services. It operates under the guidance of the Ministry of National Defense, ensuring a strong commitment to both military and civilian healthcare.
The hospital's mission includes leading in clinical medicine, teaching, and research, striving to offer exemplary care in specialized fields such as oncology, cardiovascular medicine, and organ transplantation—each critical to advancing health outcomes for patients.
Frequently Asked Questions
What is the Proteus®ONE system?
The Proteus®ONE system is a compact proton therapy solution designed to deliver targeted cancer treatments using advanced technology.
What is DynamicARC®?
DynamicARC® is an innovative beam delivery system under development by IBA to enhance the precision of proton treatments.
How many Proteus®ONE systems has IBA delivered to Taiwan?
This marks the third Proteus®ONE system ordered in Taiwan, showcasing the increasing demand for proton therapy in the region.
When is the expected start of treatments at the hospital?
The Tri-Service General Hospital aims to begin patient treatments utilizing the new system by late 2028.
Where is IBA headquartered?
IBA is headquartered in Louvain-La-Neuve, Belgium, and is a leading provider in proton therapy technology.
